Jean‐Yves Blay

Top papers

• Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

  Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla, et al.·2012·The Lancet
  ↗ 2,066OA
• Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

  David M. Hyman, Igor Puzanov, Vivek Subbiah, et al.·2015·New England Journal of Medicine
  ↗ 1,724OA
• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

  Jaap Verweij, Paolo G. Casali, John Zalcberg, et al.·2004·The Lancet
  ↗ 1,666
• Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Paolo G. Casali, N. Abecassis, Sebastian Bauer, et al.·2018·Annals of Oncology
  ↗ 1,607OA
• Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

  George D. Demetri, Peter Reichardt, Yoon‐Koo Kang, et al.·2012·The Lancet
  ↗ 1,396OA
• Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

  Carola H. Ries, Michael A. Cannarile, Sabine Hoves, et al.·2014·Cancer Cell
  ↗ 1,352
• Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

  Ian Judson, Jaap Verweij, Hans Gelderblom, et al.·2014·The Lancet Oncology
  ↗ 1,152OA
• Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

  Alessandro Gronchi, Aisha Miah, Angelo Paolo Dei Tos, et al.·2021·Annals of Oncology
  ↗ 947OA
• CD4<b>+</b>CD25<b>+</b> regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

  François Ghiringhelli, Cédric Menard, Magali Terme, et al.·2005·The Journal of Experimental Medicine
  ↗ 918OA
• KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

  Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne, et al.·2006·European Journal of Cancer
  ↗ 897
• Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

  Andrés J.M. Ferreri, Jean‐Yves Blay, Michele Reni, et al.·2003·Journal of Clinical Oncology
  ↗ 833
• Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

  Isabelle Ray‐Coquard, Claire Cropet, M. van Glabbeke, et al.·2009·Cancer Research
  ↗ 790OA